RxDoctor Payments Data

Kingsley Chin, MD

Otolaryngology · Atlanta, GANPI 1184799751

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $4,754 of the $6,032 with a category attached, or 78.8%. 24 manufacturers reported payments, led by Aerin Medical Inc. at 27.7% of the total. 2025 is the largest year on record at $2,434, 3.9 times the $628 reported in 2019. Among otolaryngology clinicians in GA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$6,032in general payments, 2019–2025

Across 155 payments — averaging $38.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Aerin Medical Inc.$2K
  • Sanofi$797
  • Regeneron Healthcare Solutions, Inc.$620
  • GSK$540
  • Medical Device Business Services, Inc.$498
  • Optinose US, Inc.$495
  • plus $1K from 18 others

What the payments were for

  • Travel & lodging$1,14619%
  • Food & beverage$4,75479%
  • Education$1322%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,032 in reported general payments places this provider in the 90th percentile of 308 otolaryngology providers in Georgia.

See all otolaryngology providers in Georgia

Medicare billing

Part B allowed, 2024
$212,474
Medicare patients
571
Services billed
2,957

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Ipratropium Bromide77$2,797
Azelastine Hcl82$2,587
Epinephrine19$2,044
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav56$592
Fluocinolone Acetonide Oil14$485
Montelukast Sodium25$425
Cefdinir17$258
Levocetirizine Dihydrochloride41$251
Ofloxacin11$243
Omeprazole28$198
Doxycycline Hyclate18$190
Fluticasone Propionate19$187
Clindamycin Hcl15$113
Prednisone29$96
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim12$87

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Hikma Pharmaceuticals USAEpinephrine$91$2,04419 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 308 otolaryngology providers in Georgia.

Other otolaryngology in Atlanta

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →